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fSTEOARTHRITIS (OA) can be described as the degra-
ation and loss of articular cartilage, accompanied
y bone remodelling, changes in osteophyte for-
ation and inflammation of the surrounding
ynovium, clinically reflected by a gradual
evelopment of fluctuating joint pain, swelling,
ti#ness and loss of motion.
There is now reliable evidence that the
nitiation and progression of OA is complex,
nd likely a result of di#erent processes. This
orkshop discussed the di#erent mechanisms
elieved to be responsible for the progression
f OA.
Although commonly considered a disease pri-
arily involving cartilage, studies support vari-
ble roles for synovium, muscle, ligaments and
one. Tissue cross-talking inside the OA joint is
riven by numerous factors including inflam-
atory cytokines and several growth factors.
eeping in mind that the joint must be considered
s a whole, a complex relationship between
ubchondral bone and cartilage is currently being
tressed as a major pathophysiological factor in
A progression. Clinically observed episodic acute
ymptomatic inflammatory eruptions seem to be
ssociated with a slow permanent asymptomatic
rocess, where the balance in anabolic and
atabolic processes is disrupted, favouring
artilage catabolism.
The exact role of several inflammatory cytokines
nd growth factors has not yet been definitively
stablished, nor has the existence of a functional
ierarchy between them. Their net e#ect depends
ot only on absolute levels, but also on a complex
nterplay among ambient cytokines and growth
actors with cell-membrane receptors, including306their number and distribution in the joint, as well
as the presence of natural antagonists.
These multiple time-dependent events are di$-
cult to reproduce collectively in animal models,
and impossible to stimulate in vitro. As there are
currently no quantitative non-invasive methods to
study the e#ect of a substance on human cartilage
in vivo, most information on the role of cytokines
and drugs has come from short-term organ culture
studies.
Today, in-vitro and animal model studies have
substantiated interesting new findings, including:
(1) Interleukin (IL)-1â is of pivotal importance in
cartilage destruction, while tumor necrosis
factor (TNF)-Æ drives the inflammatory pro-
cess. These two cytokines are prime targets in
the therapeutic approach to treatment of OA.
(2) Prostaglandin (PG) E2 is produced in large
quantities by the inflamed synovial mem-
brane. A complex interaction exists between
PGE2 and IL-1â that increases the release of
both. As control of synovitis in OA improves
symptoms and function, PGE2 remains an
important target.
(3) Changes in metabolic activity of chondrocytes
can be modulated by drug intervention. It is
now important to determine whether the drug
therapy itself does not exacerbate the prob-
lem. If the synthesis of extra-cellular matrix is
reduced, the result is an eventual deteriora-
tion of the physical properties of the matrix
and an acceleration of the synovial changes
involved in OA. Conversely, the ability to
resynthesize matrix may confer the potential
for repair and regeneration. Even in severe
OA, human articular chondrocytes retain the
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Potential targets
Cartilage Catabolism
Anabolism
Proteases, NO
growth factors
Synovium Cytokines IL-1, TNF-Æ, . . .
Antiinflammatory cytokines IL-4, IL-10, IL-13
Cytokine receptor antagonist IL-1Ra
Subchondral bone Bone remodeling factors IGF-1, uPA, . . .
Cartilage catabolic factors TGF-â
Risk factors Obesity
Trauma
IL=interleukin; TNF=tumor necrosis factor; IGF=insulin-like growth factor; TGF=transforming growth
factor; IL-1Ra=interleukin-1 receptor antagonist; PA=plasminogen activator.ability to synthesize new matrix components,
although sometimes only a minority of
chondrocytes demonstrate this function.
(4) Nonsteroidal antiinflammatory drugs
(NSAID) appear to share some degree of
similarity in that they inhibit PGE2 synthesis.
However, strong di#erences exist among them
with regard to other activities, such as the
inhibition of IL-1â synthesis, toxicity against
normal and OA chondrocytes, activity on
cartilage matrix synthesis, and so forth.
A clearer understanding of the pathophysiology
of OA permits a more accurate identification of
targets which may have potential therapeutic
value in treatment aimed at specifically and e#ec-
tively retarding the progression of this disease
(Table I).
Present data suggest the validity of a new classi-
fication of NSAIDs based on pharmacological
in-vitro e#ects regarding their potential to alter
degenerative and repair processes in OA. A broad
spectrum of synergistic activities would be prefer-
able. This workshop focused on this important
issue.
Considering that controversy remains as to
whether NSAID can a#ect the progression of OA
in humans, how relevant is the extrapolation of
in-vitro and animal data to in-vivo situations?
(1) Limited in-vivo research supports some of the
extensive, previously published in-vitro and
ex-vivo data, and encourages a possible
extrapolation.(2) Recent studies with indomethacin appear to
suggest that in-vitro and ex-vivo data show
similar results to in-vivo clinical experiments;
i.e., an increased rate of OA degeneration.
(3) A favourable structure-modifying influence of
NSAID on OA progression, however, has not
yet been clinically demonstrated.
No doubt, further basic and clinical research is
necessary. This will be stimulated by recently
published guidelines that strongly recommend the
evaluation of both the symptomatic and structural
e#ects of drugs used to treat OA.
Changes in the joint space width (JSW) in
patients with knee OA are increasingly accepted
as markers to monitor disease progression and/or
e$cacy of drug treatment. Standardized computer-
ized macroradiography improves measurement
precision and accuracy, allowing the detection of
significant changes in JSW and osteophyte size
within 18 months on an attainable number of
patients. It is now possible to conduct long-term
clinical studies focusing on the structural evalu-
ation of the treatment e#ect of NSAID following
daily intake.
Pending results from such studies, and based on
the above findings—in addition to the ever-present
concern for e$cacy and safety—physicians should
bear in mind that NSAID do a#ect cartilage metab-
olism. Practitioners should concentrate on treat-
ment which favours a balance in catabolic and
anabolic processes over that which does not.
